Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN2 | P17706 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 3/20 | 0.51 |
| ▸ | HPGDS | O60760 | 3/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | CHRND | Q07001 | 6/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.47 |
| ▸ | CHRNG | P07510 | 2/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.47 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5594950 | 1.00 | PTPN2 (0.52) | PTPN2PTPN1ACEHPGDSCA12 | |
| Hydrochloric Acid SCHEMBL12469709 | 0.98 | PTPN2 (0.51) | PTPN2PTPN1ACEHPGDSCA12 | |
| SCHEMBL26605060 | 0.90 | OPRD1 (0.48) | PTPN2PTPN1ACEHPGDSCHRND | |
| SCHEMBL26605068 | 0.90 | OPRD1 (0.48) | PTPN2PTPN1ACEHPGDSCHRND | |
| SCHEMBL30316218 | 0.89 | PTPN1 (0.58) | PTPN2PTPN1ACECHRNDCHRNA1 | |
| SCHEMBL6757142 | 0.87 | PTPN2 (0.52) | PTPN2PTPN1ACEHPGDSCA12 | |
| SCHEMBL7110134 | 0.87 | ACE (0.60) | ACECA1CHRNDCHRNA1CHRNG | |
| SCHEMBL3459805 | 0.87 | ACE (0.60) | ACECA1CHRNDCHRNA1CHRNG | |
| SCHEMBL7110125 | 0.87 | ACE (0.60) | ACECA1CHRNDCHRNA1CHRNG | |
| SCHEMBL479126 | 0.87 | ACE (0.60) | ACECA1CHRNDCHRNA1CHRNG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2026-04-23 | — | — | US | claimed |
| US-11851468-B2 | Treatment of neurological diseases | UNIVERSITY OF LANCASTER (GB) | 2023-12-26 | — | — | US | claimed |
| US-20230071112-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-03-09 | — | — | US | claimed |
| US-20220313836-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2022-10-06 | — | — | US | claimed |
| EP-4018997-A1 | N-LIPOIC -AMINO ACID OR PEPTIDE, DERIVATIVES AND THEIR USES | NeoStrata Company, Inc. (US) | 2022-06-29 | — | — | EP | claimed |
| US-5298491-A | Derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present | IMMUNOTECH (FR) | 1994-03-29 | — | — | US | claimed |
| US-20260063648-A1 | Method for the prediction of a risk or severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cell therapy (IECT) | PAM THERAGNOSTICS GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2026-01-20 | — | — | US | disclosed |
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-12-30 | — | — | US | disclosed |
| US-12435056-B2 | N-lipoic-amino acid or peptide, derivatives and their uses | NEOSTRATA COMPANY, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-07-22 | — | — | US | disclosed |
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2025-05-20 | — | — | US | disclosed |
| US-20250154219-A1 | PEPTIDE ANALOGS | ADEPTHERA LLC | 2025-05-15 | — | — | US | disclosed |
| WO-2001087287-A2 | USE OF PYRAZOLE DERIVATIVES FOR TREATING INFERTILITY | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2001-11-22 | — | — | WO | disclosed |
| EP-1104438-A2 | NOVEL ANTI-DIABETIC PEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2001-06-06 | — | — | EP | disclosed |
| WO-2000011029-A2 | NOVEL ANTI-DIABETIC PEPTIDES | AMYLIN PHARMACEUTICALS, INC. (US) | 2000-03-02 | — | — | WO | disclosed |
| EP-0457701-B1 | Derivatives of endogenous mediators, their salts, process for preparation, application and compositions containing them | IMMUNOTECH SA (FR) | 1995-02-22 | — | — | EP | disclosed |
| US-5298491-A | Derivatives of endogenous mediators, their salts, method of preparation, applications and compositions in which they are present | IMMUNOTECH (FR) | 1994-03-29 | — | — | US | disclosed |
| EP-0457701-A1 | Derivatives of endogenous mediators, their salts, process for preparation, application and compositions containing them | IMMUNOTECH S.A. (FR) | 1991-11-21 | — | — | EP | disclosed |
| US-4818683-A | Immunoassay for monoamines | IMMUNOTECH (FR) | 1989-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12508321-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD4, CD2, B2M | PTPN2 2675/4885PTPN1 2381/4885ACE 3561/4885 |
| US-12435056-B2 | N-lipoic-amino acid or peptide, derivatives and their uses | CUTA, ALAD, NACA | PTPN2 1241/4885PTPN1 1329/4885ACE 1877/4885 |
| US-20250154219-A1 | PEPTIDE ANALOGS | RAMP1, RAMP2, RAMP3 | PTPN2 1816/4885PTPN1 1782/4885ACE 2255/4885 |
| US-20220313836-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | PTPN2 3853/4885PTPN1 3907/4885ACE 4146/4885 |
| US-12303571-B2 | Specific conjugation linkers, specific immunoconjugates thereof, methods of making and uses such conjugates thereof | SLC25A1, GCDH, FH | PTPN2 3615/4885PTPN1 3946/4885ACE 3845/4885 |
| US-20260063648-A1 | Method for the prediction of a risk or severity of side effects in a cancer patient that is to be treated or has been treated with immune effector cell therapy (IECT) | KLKB1, EPCAM, ECE1 | PTPN2 1650/4885PTPN1 1621/4885ACE 1206/4885 |
| US-20260108619-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | DCLRE1A, CCR3, CCR8 | PTPN2 2272/4885PTPN1 1785/4885ACE 4519/4885 |
| US-12364767-B2 | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers | CD2BP2, DCLRE1A, EPCAM | PTPN2 3853/4885PTPN1 3907/4885ACE 4146/4885 |
| US-12528827-B2 | Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors | F2RL3, F2R, PF4 | PTPN2 805/4885PTPN1 561/4885ACE 1998/4885 |
| US-20230071112-A1 | CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS | CD2BP2, DCLRE1A, EPCAM | PTPN2 3807/4885PTPN1 3811/4885ACE 4174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.